XORTX Therapeutics Valuation
| XRTX Stock | 1.75 0.01 0.57% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. XORTX Therapeutics maintains a prevalent Real Value of USD1.68 per share. The last-minute price of the company is USD1.75. Our model calculates the value of XORTX Therapeutics from analyzing the company fundamentals such as Shares Owned By Insiders of 3.01 %, return on asset of -0.33, and Current Valuation of 2.5 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting XORTX Therapeutics' valuation include:
Price Book 1.8848 | Enterprise Value 2.5 M | Enterprise Value Ebitda (1.50) | Forward PE 0.9658 | Trailing PE 10.2941 |
Overvalued
Today
Please note that XORTX Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of XORTX Therapeutics is based on 3 months time horizon. Increasing XORTX Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the XORTX stock is determined by what a typical buyer is willing to pay for full or partial control of XORTX Therapeutics. Since XORTX Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of XORTX Stock. However, XORTX Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.75 | Real 1.68 | Hype 1.75 | Naive 1.72 |
The intrinsic value of XORTX Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence XORTX Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of XORTX Therapeutics helps investors to forecast how XORTX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of XORTX Therapeutics more accurately as focusing exclusively on XORTX Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use XORTX Therapeutics' intrinsic value based on its ongoing forecasts of XORTX Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against XORTX Therapeutics' closest peers.
XORTX Therapeutics Cash |
|
XORTX Valuation Trend
Analysing the historical paterns of XORTX Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of XORTX Therapeutics over time and is usually enough for investors to make rational market timing decisions.
XORTX Therapeutics Total Value Analysis
XORTX Therapeutics is at this time anticipated to have takeover price of 2.5 M with market capitalization of 5.64 M, debt of 825.94 K, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the XORTX Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.5 M | 5.64 M | 825.94 K |
XORTX Therapeutics Asset Utilization
One of the ways to look at asset utilization of XORTX is to check how much profit was generated for every dollar of assets it reports. XORTX Therapeutics maintains a negative usage of resources of -0.33 (%), losing USD0.003314 for each dollar of resources held by the company. Inadequate asset utilization attests that the company is being less efficient with each dollar of resources it maintains. Specifically, asset utilization of XORTX Therapeutics shows how discouraging it operates for each dollar spent on its resources.XORTX Therapeutics Ownership Allocation
XORTX Therapeutics maintains 3.01 (%) of its outstanding shares held by insiders and 6.03 (%) owned by institutional investors.XORTX Therapeutics Profitability Analysis
Net Loss for the year was (2.16 M) with profit before overhead, payroll, taxes, and interest of 0.About XORTX Therapeutics Valuation
Our relative valuation model uses a comparative analysis of XORTX Therapeutics. We calculate exposure to XORTX Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of XORTX Therapeutics's related companies.Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.